Evaluation of diagnostic test and curative effect for the superficial bladder cancer based oral 5-aminolevulinic acid (5-ALA) prior to transurethral resection (TUR)

Evaluation of diagnostic test and curative effect for the superficial bladder cancer based oral 5-aminolevulinic acid (5-ALA) prior to transurethral resection (TUR) - The significance of oral 5-aminolevulinic acid (5-ALA) for superficial bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035009

Enrollment

500

Registered

2018-11-26

Start date

2018-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

superficial bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: superficial cancer

Exclusion criteria

Exclusion criteria: progressive cancer

Design outcomes

Primary

Measure	Time frame
We study to confirm the superficial bladder cancer by parts of bladder with oral 5-ALA(20mg/kg) prior to TUR	—

Secondary

Measure	Time frame
To evaluate the recurrence rate by parts of bladder with oral(20mg/kg) 5-ALA prior to TUR at 3, 6, 9 and 12 months later from TUR	—

Countries

Japan

Contacts

Public ContactHironori Betsunoh

Dokkyo Medical University Urology

hirobets@dokkyomed.ac.jp0282872162

Outcome results